면역측정 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 기술별, 용도별, 최종 용도별, 검체별, 지역별 및 부문별 예측(2026-2033년)

Immunoassay Market Summary

The global immunoassay market size was estimated at USD 28.05 billion in 2025 and is projected to reach USD 40.25 billion by 2033, growing at a CAGR of 4.63% from 2026 to 2033, driven by increasing demand for precision medicine. Immunoassays play a crucial role in tailoring treatments to individual patients by identifying biomarkers that predict responses to specific therapies.

The rising prevalence of cancer, cardiovascular diseases, and autoimmune disorders has driven the need for targeted therapies, where immunoassays help determine the most effective treatment for patients. This approach minimizes adverse effects and enhances treatment efficacy, improving patient outcomes. The shift from a one-size-fits-all treatment approach to personalized medicine is a primary driver of market expansion. Furthermore, pharmaceutical companies are increasingly integrating immunoassays into drug development pipelines to improve the success rate of novel therapeutics, further accelerating market growth.

Global Immunoassay Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends across sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global immunoassay market report based on product, specimen, technology, application, end-use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Reagents & Kits
  • ELISA Reagents & Kits
  • Rapid Tests Reagents & Kits
  • ELISPOT Reagents & Kits
  • Western Blot Reagents & Kits
  • Other Reagents & Kits
• Analyzers/Instruments
  • Open-Ended Systems
  • Closed-Ended Systems
• Software & Services
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Therapeutic Drug Monitoring
• Oncology
• Cardiology
• Endocrinology
• Infectious Disease Testing
• Autoimmune Diseases
• Others
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Radioimmunoassay (RIA)
• Enzyme Immunoassays (EIA)
  • Chemiluminescence Immunoassays (CLIA)
  • Fluorescence Immunoassays (FIA)
• Rapid Test
• Others
• Specimen Outlook (Revenue, USD Million, 2021 - 2033)
• Blood
• Saliva
• Urine
• Others
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Blood Banks
• Clinical Laboratories
• Pharmaceutical and Biotech Companies
• Academic Research Centers
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Immunoassay Market Variables, Trends, & Scope

• 3.1. Market Introduction/Lineage Outlook
• 3.2. Market Size and Growth Prospects (USD Million)
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
    • 3.3.1.1. Rising incidence of chronic and infectious diseases
    • 3.3.1.2. Increasing demand for point-of-care diagnostics
    • 3.3.1.3. Growing demand for portable and automated immunoassays
  • 3.3.2. Market Restraints Analysis
    • 3.3.2.1. Lower detection limit
    • 3.3.2.2. Limitations associated with immunoassay techniques
• 3.4. Immunoassay Market Analysis Tools
  • 3.4.1. Porter's Five Forces Analysis
    • 3.4.1.1. Bargaining power of the suppliers
    • 3.4.1.2. Bargaining power of the buyers
    • 3.4.1.3. Threats of substitution
    • 3.4.1.4. Threats from new entrants
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Economic and Social landscape
    • 3.4.2.3. Technological landscape
    • 3.4.2.4. Environmental landscape
    • 3.4.2.5. Legal landscape

Chapter 4. Immunoassay Market: Product Estimates & Trend Analysis

• 4.1. Immunoassay Market: Product Movement Analysis
• 4.2. Immunoassay Market Estimates and Forecasts, by Product (USD Million), 2025 & 2033
• 4.3. Assays, Kits, and Reagents
  • 4.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3.2. ELISA Reagents & Kits
    • 4.3.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3.3. Rapid Tests Reagents & Kits
    • 4.3.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3.4. ELISPOT Reagents & Kits
    • 4.3.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3.5. Western Blot Reagents & Kits
    • 4.3.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3.6. Other Reagents & Kits
    • 4.3.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.4. Analyzers/Instruments
  • 4.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.2. Open Ended Systems
    • 4.4.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.3. Closed Ended Systems
    • 4.4.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Software and Services
  • 4.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Immunoassay Market: Application Estimates & Trend Analysis

• 5.1. Immunoassay Market: Application Movement Analysis
• 5.2. Immunoassay Market Estimates and Forecasts, by Application (USD Million), 2025 & 2033
• 5.3. Therapeutic Drug Monitoring
  • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.4. Oncology
  • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Cardiology
  • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Endocrinology
  • 5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Infectious Disease Testing
  • 5.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.8. Autoimmune Diseases
  • 5.8.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.9. Others
  • 5.9.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Immunoassay Market: Technology Estimates & Trend Analysis

• 6.1. Immunoassay Market: Technology Movement Analysis
• 6.2. Immunoassay Market Estimates and Forecasts, by Technology (USD Million), 2025 & 2033
• 6.3. Radioimmunoassay (RIA)
  • 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.4. Enzyme Immunoassays (EIA)
  • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.2. Chemiluminescence Immunoassays (CLIA)
    • 6.4.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.3. Fluorescence Immunoassays (FIA)
    • 6.4.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Rapid Test
  • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Others
  • 6.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Immunoassay Market: Specimen Estimates & Trend Analysis

• 7.1. Immunoassay Market: Specimen Movement Analysis
• 7.2. Immunoassay Market Estimates and Forecasts, by Specimen (USD Million), 2025 & 2033
• 7.3. Blood
  • 7.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.4. Saliva
  • 7.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Urine
  • 7.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Others
  • 7.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Immunoassay Market: End Use Estimates & Trend Analysis

• 8.1. Immunoassay Market: End-use Movement Analysis
• 8.2. Immunoassay Market Estimates and Forecasts, by End Use (USD Million), 2025 & 2033
• 8.3. Hospitals
  • 8.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.4. Blood Banks
  • 8.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Clinical Laboratories
  • 8.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Pharmaceutical and Biotech Companies
  • 8.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.7. Academic Research Centers
  • 8.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.8. Others
  • 8.8.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Immunoassay Market: Regional Estimates & Trend Analysis

• 9.1. Immunoassay Market Share, By Region, 2025 & 2033, USD Million
• 9.2. North America
  • 9.2.1. North America Immunoassay Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.2.2. U.S.
    • 9.2.2.1. Key Country Dynamics
    • 9.2.2.2. Target Disease Prevalence
    • 9.2.2.3. Competitive Scenario
    • 9.2.2.4. Regulatory Framework
    • 9.2.2.5. Reimbursement Scenario
    • 9.2.2.6. U.S. Immunoassay Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.2.3. Canada
    • 9.2.3.1. Key Country Dynamics
    • 9.2.3.2. Target Disease Prevalence
    • 9.2.3.3. Competitive Scenario
    • 9.2.3.4. Regulatory Framework
    • 9.2.3.5. Reimbursement Scenario
    • 9.2.3.6. Canada Immunoassay Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.2.4. Mexico
    • 9.2.4.1. Key Country Dynamics
    • 9.2.4.2. Target Disease Prevalence
    • 9.2.4.3. Competitive Scenario
    • 9.2.4.4. Regulatory Framework
    • 9.2.4.5. Reimbursement Scenario
    • 9.2.4.6. Mexico Immunoassay Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.3. Europe
  • 9.3.1. Europe Immunoassay Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.3.2. UK
    • 9.3.2.1. Key Country Dynamics
    • 9.3.2.2. Target Disease Prevalence
    • 9.3.2.3. Competitive Scenario
    • 9.3.2.4. Regulatory Framework
    • 9.3.2.5. Reimbursement Scenario
    • 9.3.2.6. UK Immunoassay Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.3.3. Germany
    • 9.3.3.1. Key Country Dynamics
    • 9.3.3.2. Target Disease Prevalence
    • 9.3.3.3. Competitive Scenario
    • 9.3.3.4. Regulatory Framework
    • 9.3.3.5. Reimbursement Scenario
    • 9.3.3.6. Germany Immunoassay Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.3.4. France
    • 9.3.4.1. Key Country Dynamics
    • 9.3.4.2. Target Disease Prevalence
    • 9.3.4.3. Competitive Scenario
    • 9.3.4.4. Regulatory Framework
    • 9.3.4.5. Reimbursement Scenario
    • 9.3.4.6. France Immunoassay Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.3.5. Italy
    • 9.3.5.1. Key Country Dynamics
    • 9.3.5.2. Target Disease Prevalence
    • 9.3.5.3. Competitive Scenario
    • 9.3.5.4. Regulatory Framework
    • 9.3.5.5. Reimbursement Scenario
    • 9.3.5.6. Italy Immunoassay Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.3.6. Spain
    • 9.3.6.1. Key Country Dynamics
    • 9.3.6.2. Target Disease Prevalence
    • 9.3.6.3. Competitive Scenario
    • 9.3.6.4. Regulatory Framework
    • 9.3.6.5. Reimbursement Scenario
    • 9.3.6.6. Spain Immunoassay Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.3.7. Denmark
    • 9.3.7.1. Key Country Dynamics
    • 9.3.7.2. Target Disease Prevalence
    • 9.3.7.3. Competitive Scenario
    • 9.3.7.4. Regulatory Framework
    • 9.3.7.5. Reimbursement Scenario
    • 9.3.7.6. Denmark Immunoassay Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.3.8. Sweden
    • 9.3.8.1. Key Country Dynamics
    • 9.3.8.2. Target Disease Prevalence
    • 9.3.8.3. Competitive Scenario
    • 9.3.8.4. Regulatory Framework
    • 9.3.8.5. Reimbursement Scenario
    • 9.3.8.6. Sweden Immunoassay Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.3.9. Norway
    • 9.3.9.1. Key Country Dynamics
    • 9.3.9.2. Target Disease Prevalence
    • 9.3.9.3. Competitive Scenario
    • 9.3.9.4. Regulatory Framework
    • 9.3.9.5. Reimbursement Scenario
    • 9.3.9.6. Norway Immunoassay Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.4. Asia Pacific
  • 9.4.1. Asia Pacific Immunoassay Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.2. Japan
    • 9.4.2.1. Key Country Dynamics
    • 9.4.2.2. Target Disease Prevalence
    • 9.4.2.3. Competitive Scenario
    • 9.4.2.4. Regulatory Framework
    • 9.4.2.5. Reimbursement Scenario
    • 9.4.2.6. Japan Immunoassay Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.3. China
    • 9.4.3.1. Key Country Dynamics
    • 9.4.3.2. Target Disease Prevalence
    • 9.4.3.3. Competitive Scenario
    • 9.4.3.4. Regulatory Framework
    • 9.4.3.5. Reimbursement Scenario
    • 9.4.3.6. China Immunoassay Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.4. India
    • 9.4.4.1. Key Country Dynamics
    • 9.4.4.2. Target Disease Prevalence
    • 9.4.4.3. Competitive Scenario
    • 9.4.4.4. Regulatory Framework
    • 9.4.4.5. Reimbursement Scenario
    • 9.4.4.6. India Immunoassay Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.5. Australia
    • 9.4.5.1. Key Country Dynamics
    • 9.4.5.2. Target Disease Prevalence
    • 9.4.5.3. Competitive Scenario
    • 9.4.5.4. Regulatory Framework
    • 9.4.5.5. Reimbursement Scenario
    • 9.4.5.6. Australia Immunoassay Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.6. South Korea
    • 9.4.6.1. Key Country Dynamics
    • 9.4.6.2. Target Disease Prevalence
    • 9.4.6.3. Competitive Scenario
    • 9.4.6.4. Regulatory Framework
    • 9.4.6.5. Reimbursement Scenario
    • 9.4.6.6. South Korea Immunoassay Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.7. Thailand
    • 9.4.7.1. Key Country Dynamics
    • 9.4.7.2. Target Disease Prevalence
    • 9.4.7.3. Competitive Scenario
    • 9.4.7.4. Regulatory Framework
    • 9.4.7.5. Reimbursement Scenario
    • 9.4.7.6. Thailand Immunoassay Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.5. Latin America
  • 9.5.1. Latin America Immunoassay Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.2. Brazil
    • 9.5.2.1. Key Country Dynamics
    • 9.5.2.2. Target Disease Prevalence
    • 9.5.2.3. Competitive Scenario
    • 9.5.2.4. Regulatory Framework
    • 9.5.2.5. Reimbursement Scenario
    • 9.5.2.6. Brazil Immunoassay Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.3. Argentina
    • 9.5.3.1. Key Country Dynamics
    • 9.5.3.2. Target Disease Prevalence
    • 9.5.3.3. Competitive Scenario
    • 9.5.3.4. Regulatory Framework
    • 9.5.3.5. Reimbursement Scenario
    • 9.5.3.6. Argentina Immunoassay Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.6. Middle East and Africa
  • 9.6.1. Middle East and Africa Immunoassay Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.2. South Africa
    • 9.6.2.1. Key Country Dynamics
    • 9.6.2.2. Target Disease Prevalence
    • 9.6.2.3. Competitive Scenario
    • 9.6.2.4. Regulatory Framework
    • 9.6.2.5. Reimbursement Scenario
    • 9.6.2.6. South Africa Immunoassay Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.3. Saudi Arabia
    • 9.6.3.1. Key Country Dynamics
    • 9.6.3.2. Target Disease Prevalence
    • 9.6.3.3. Competitive Scenario
    • 9.6.3.4. Regulatory Framework
    • 9.6.3.5. Reimbursement Scenario
    • 9.6.3.6. Saudi Arabia Immunoassay Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.4. UAE
    • 9.6.4.1. Key Country Dynamics
    • 9.6.4.2. Target Disease Prevalence
    • 9.6.4.3. Competitive Scenario
    • 9.6.4.4. Regulatory Framework
    • 9.6.4.5. Reimbursement Scenario
    • 9.6.4.6. UAE Immunoassay Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.5. Kuwait
    • 9.6.5.1. Key Country Dynamics
    • 9.6.5.2. Target Disease Prevalence
    • 9.6.5.3. Competitive Scenario
    • 9.6.5.4. Regulatory Framework
    • 9.6.5.5. Reimbursement Scenario
    • 9.6.5.6. Kuwait Immunoassay Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Recent Developments & Impact Analysis by Key Market Participants
• 10.2. Company Categorization
• 10.3. Company Heat Map Analysis
• 10.4. Company Profiles
• 10.5. Abbott
  • 10.5.1. Participant's Overview
  • 10.5.2. Financial Performance
  • 10.5.3. Product Benchmarking
  • 10.5.4. Recent Developments/ Strategic Initiatives
• 10.6. Siemens Healthineers AG
  • 10.6.1. Participant's Overview
  • 10.6.2. Financial Performance
  • 10.6.3. Product Benchmarking
  • 10.6.4. Recent Developments/ Strategic Initiatives
• 10.7. Danaher Corporation (Beckman Coulter)
  • 10.7.1. Participant's Overview
  • 10.7.2. Financial Performance
  • 10.7.3. Product Benchmarking
  • 10.7.4. Recent Developments/ Strategic Initiatives
• 10.8. bioMerieux SA
  • 10.8.1. Participant's Overview
  • 10.8.2. Financial Performance
  • 10.8.3. Product Benchmarking
  • 10.8.4. Recent Developments/ Strategic Initiatives
• 10.9. Quidel Corporation
  • 10.9.1. Participant's Overview
  • 10.9.2. Financial Performance
  • 10.9.3. Product Benchmarking
  • 10.9.4. Recent Developments/ Strategic Initiatives
• 10.10. Sysmex Corporation
  • 10.10.1. Participant's Overview
  • 10.10.2. Financial Performance
  • 10.10.3. Product Benchmarking
  • 10.10.4. Recent Developments/ Strategic Initiatives
• 10.11. Ortho Clinical Diagnostics
  • 10.11.1. Participant's Overview
  • 10.11.2. Financial Performance
  • 10.11.3. Product Benchmarking
  • 10.11.4. Recent Developments/ Strategic Initiatives
• 10.12. Bio-Rad Laboratories, Inc.
  • 10.12.1. Participant's Overview
  • 10.12.2. Financial Performance
  • 10.12.3. Product Benchmarking
  • 10.12.4. Recent Developments/ Strategic Initiatives
• 10.13. F. Hoffmann-La Roche AG
  • 10.13.1. Participant's Overview
  • 10.13.2. Financial Performance
  • 10.13.3. Product Benchmarking
  • 10.13.4. Recent Developments/ Strategic Initiatives
• 10.14. Becton, Dickinson, and Company
  • 10.14.1. Participant's Overview
  • 10.14.2. Financial Performance
  • 10.14.3. Product Benchmarking
  • 10.14.4. Recent Developments/ Strategic Initiatives
• 10.15. Thermo Fisher Scientific, Inc.
  • 10.15.1. Participant's Overview
  • 10.15.2. Financial Performance
  • 10.15.3. Product Benchmarking
  • 10.15.4. Recent Developments/ Strategic Initiatives